<DOC>
	<DOCNO>NCT01194804</DOCNO>
	<brief_summary>The objective study assess long term safety Eculizumab hemolytic PNH patient complete 4 week screen 12 week treatment period C07-001 study . In addition , pharmacokinetic pharmacodynamic assessment Eculizumab conduct .</brief_summary>
	<brief_title>E07-001 : Safety Efficacy Extension Study Eculizumab Paroxysmal Nocturnal Hemoglobinuria Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Patients must fully complete C07001 study 12week treatment period Patients terminate early C07001 study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hemolytic Paroxysmal Nocturnal Hemoglobinuria</keyword>
	<keyword>Eculizumab</keyword>
	<keyword>PNH</keyword>
</DOC>